Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dominion Energy Inc (D) vs Medpace Holdings Inc (MEDP) Price & Performance

Dominion Energy IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Dominion Energy Inc vs Medpace Holdings Inc — how do they compare? Dominion Energy Inc trades at $61.75 (market cap $54.12B), while Medpace Holdings Inc trades at $602 (market cap $16.87B). The key difference: Dominion Energy Inc is far larger — about 3.2× Medpace Holdings Inc's market cap, and Dominion Energy Inc pays a 4.34% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and Medpace Holdings Inc for 14 Days on average.

DMEDP
Market Cap
$54.12B$16.87B
Volume
4,249,753207,570
Sector
UtilitiesHealth
52-Week High
$71.67$630.19
52-Week Low
$57.08$393.42
Typical Hold Time
76 Days14 Days
Enterprise Value
$108.24B$16.48B
Dividend Yield
4.34%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dominion Energy Inc

Dominion Energy (D) trades at $61.75, down 0.4% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 EPS of $0.79 versus $0.681 expected, continuing a pattern of exceeding expectations. Fundamentals show improving revenue growth to $16.51B in 2025 and net income margin expansion to 13.99%, though cash flow trends show significant capital investments. The pending merger with NextEra Energy dominates recent news coverage, with regulators reviewing a proposed $1 billion annual Virginia supplier program.

Dominion Energy presents a mixed investment case with solid fundamental performance offset by technical weakness and merger execution risks. The stock trades below analyst consensus target of $71.56, offering potential upside if the NextEra merger proceeds smoothly. Key risks include regulatory approval uncertainty, high capital expenditure requirements, and interest rate sensitivity given the company's substantial debt load of $37.31B long-term.

Medpace Holdings Inc

MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.

MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

D

No sentiment data available yet.

MEDP
100% Buy0% Sell
Avg holding period · 14 Days

Top news

Latest headlines on both assets

About Dominion Energy Inc

Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.

Read more on D →

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP →